Skip to content
OpenCapital
Get started

Organon OGN China — Revenue

Other geography segments

U.S.
$388M—

Similar metrics at other companies

10x Genomics, Inc. logo
TXGChina — Revenue
$15.84M-6.2%
Belden logo
BDCChina — Revenue
$24.81M+7.7%
Silicon Laboratories logo
SLABChina — Revenue
$67.32M+14.6%
SPX Technologies logo
SPXCCHINA — Revenue
$17M+30.8%
UCT
UCTTChina — Total revenues
$24.8M-25.5%
Regal Rexnord logo
RRXChina — Revenue
$78.45M-2.9%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%—
Debt / equity9.5×-7.0×
Current ratio2×+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's china — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's china — revenue?
Organon (OGN) reported china — revenue of $194M in Q1 2026.
How has Organon's china — revenue changed year-over-year?
Organon's china — revenue decreased by 4.9% year-over-year, from $204M to $194M.
What is the long-term trend for Organon's china — revenue?
Over 4 years (2021 to 2025), Organon's china — revenue has grown at a -2.9% compound annual growth rate (CAGR), from $934M to $829M.
What does china — revenue mean?
This metric represents the total net sales generated from pharmaceutical products sold within the China geographic market. It reflects the company's commercial performance and market penetration in this specific region across its portfolio of women's health, biosimilars, and established brands. Monitoring this figure helps investors assess the company's regional growth trajectory and exposure to local healthcare policy and competitive dynamics.